Clinical Trial Update: Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv [Phase 4]

View source ↗

Summary

Phase 4 open-label, randomized two-way crossover trial comparing oral and intravenous esomeprazole for Gastroesophageal reflux disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Nexium (esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: Gastroesophageal Reflux Disease | Phase 4 | Status: COMPLETED